Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2021, Quick Ratio deteriorated to 0.85 a new company low.

Within Major Pharmaceutical Preparations industry 569 other companies have achieved higher Quick Ratio than Orphazyme A in fourth quarter 2021. While Quick Ratio total ranking in the fourth quarter 2021 has deteriorated compared to the prior quarter from 0 to 3734.

Explain Quick Ratio?
How much Cash & cash equivalents ORPH�s has?
What are ORPH�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ORPH Quick Ratio	(Dec 31 2021) Q4	(Dec 31 2020) Q3	0 Q2	0 Q1	0 Q4
Y / Y Current Liabilities Change	-88.21 %	717.04 %	-	-	-
Y / Y Cash & cash equivalent Change	-97.72 %	520.69 %	-	-	-
Quick Ratio MRQ	0.85	1.01	4.4	4.4	4.4
ORPH's Total Ranking	# 3734	# 0	# 0	# 0	# 1194
Seq. Current Liabilities Change	-83.47 %	-28.68 %	0 %	0 %	1045.52 %
Seq. Cash & cash equivalent Change	-86.16 %	-83.56 %	0 %	0 %	3676.19 %

Quick Ratio fourth quarter 2021 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 570
Healthcare Sector	# 1079
Overall Market	# 3734

Quick Ratio Statistics
High	Average	Low
4.4	2.73	0.85
0		(Dec 31 2021)

Financial Statements
Orphazyme A's Current Liabilities	$ 20 Millions	Visit ORPH's Balance sheet
Orphazyme A's Cash & cash equivalent	$ 17 Millions	Visit ORPH's Balance sheet
Source of ORPH's Sales		Visit ORPH's Sales by Geography

Cumulative Orphazyme A's Quick Ratio

ORPH's Quick Ratio for the trailling 12 Months

ORPH Quick Ratio	(Dec 31 2021) 12 Months	(Dec 31 2020) 12 Months	0 12 Months	0 12 Months	0 12 Months
Y / Y Current Liabilities TTM Growth	160.39 %	4153.61 %	-	-	-
Y / Y Cash & cash equivalent TTM Growth	113.07 %	11849.25 %	-	-	-
Quick Ratio TTM	3.4	3.75	4.31	4.27	4.15
Total Ranking TTM	# 5825	# 0	# 0	# 0	# 972
Seq. Current Liabilities TTM Growth	-23.76 %	20.28 %	47.91 %	91.97 %	1145.52 %
Seq. Cash & cash equivalent TTM Growth	-30.88 %	4.56 %	49.35 %	97.42 %	3776.19 %

Quick ratio ranking by company, industry and sector >> Back to ORPH Financial Strength Comparisons >> Go to Compare ORPH Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in ORPH's Current Liabilities to $19.65 millions, cumulative Quick Ratio to 3.4 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 628 other companies have achieved higher Quick Ratio than Orphazyme A. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2020 from 0 to 5825.

Explain Quick Ratio?
How much Cash & cash equivalents ORPH�s has?
What are ORPH�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 629
Healthcare Sector	# 1239
Within the Market	# 5825

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.79	0.79	0.79
(Dec 31 2021)

Companies with similar Quick Ratio in the quarter ending Dec 31 2021, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2021 MRQ Cash & cash equivalent	Dec 31 2021 MRQ Current Liabilities
Palvella Therapeutics Inc	2.33	$ 117.764 Millions	$ 50.561 Millions
Vyne Therapeutics Inc	2.33	$ 42.855 Millions	$ 18.410 Millions
Alpine Immune Sciences Inc	2.33	$ 162.303 Millions	$ 69.778 Millions
Lunai Bioworks Inc	2.32	$ 13.708 Millions	$ 5.899 Millions
Skye Bioscience Inc	2.30	$ 8.988 Millions	$ 3.912 Millions
Alkermes Plc	2.29	$ 536.311 Millions	$ 234.070 Millions
Nanobiotix S a	2.28	$ 93.992 Millions	$ 41.266 Millions
Adial Pharmaceuticals Inc	2.28	$ 6.062 Millions	$ 2.663 Millions
Curevac N v	2.27	$ 918.415 Millions	$ 404.883 Millions
Innovation Pharmaceuticals Inc	2.23	$ 10.000 Millions	$ 4.491 Millions
Avadel Pharmaceuticals Plc	2.22	$ 51.656 Millions	$ 23.243 Millions
Ardelyx inc	2.21	$ 116.689 Millions	$ 52.821 Millions
Aditxt Inc	2.18	$ 7.872 Millions	$ 3.607 Millions
Stablecoin Development Corporation	2.18	$ 7.504 Millions	$ 3.442 Millions
Quantum Biopharma Ltd	2.17	$ 35.260 Millions	$ 16.212 Millions
Celyad Oncology Sa	2.17	$ 33.620 Millions	$ 15.486 Millions
Nabriva Therapeutics Plc	2.17	$ 47.675 Millions	$ 21.966 Millions
Pharming Group N v	2.15	$ 191.924 Millions	$ 89.244 Millions
Arrowhead Pharmaceuticals Inc	2.12	$ 311.162 Millions	$ 146.536 Millions
Checkpoint Therapeutics inc	2.11	$ 54.735 Millions	$ 25.982 Millions
Geovax Labs Inc	2.10	$ 11.435 Millions	$ 5.435 Millions
Gelesis Holdings Inc	2.08	$ 28.397 Millions	$ 13.660 Millions
Xencor Inc	2.05	$ 144.982 Millions	$ 70.738 Millions
Phasebio Pharmaceuticals Inc.	2.01	$ 41.800 Millions	$ 20.833 Millions
Thorne Healthtech Inc	1.99	$ 51.101 Millions	$ 25.737 Millions
Evotec Se	1.98	$ 809.474 Millions	$ 409.476 Millions
Myovant Sciences Ltd	1.96	$ 527.762 Millions	$ 269.037 Millions
Heron Therapeutics Inc	1.95	$ 157.580 Millions	$ 80.689 Millions
Dmk Pharmaceuticals Corporation	1.94	$ 23.251 Millions	$ 11.973 Millions
Avid Bioservices Inc	1.94	$ 149.957 Millions	$ 77.302 Millions

Date modified: 2026-09-18T13:11:04+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.